Global pharma giant Pfizer’s recent announcement of a record $1.25-billion upfront payment to buy the exclusive global license of Hong Kong-listed 3SBio’s cancer drug underscores the growing momentum displayed by big pharma towards investments in Chinese biotech assets.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
